Circulation

NOVEMBER 11, 2024

Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among Results:Among 5002 (projected to 34.0

Diabetes 40

Diabetes Blood Pressure Myocardial Infarction Kidney Disease 40

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries.

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

Open Heart

JANUARY 13, 2023

Objectives Accurate prediction of heart failure (HF) patients at high risk of atrial fibrillation (AF) represents a potentially valuable tool to inform shared decision making. No validated prediction model for AF in HF is currently available. The objective was to develop clinical prediction models for 1-year risk of AF.

Heart Failure 52

Heart Failure Atrial Fibrillation Myocardial Infarction Kidney Disease 52

European Journal of Heart Failure

JANUARY 17, 2025

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. a If patients were receiving both types of diuretics at baseline, they were included in both subgroups. Patients were analysed by baseline diuretic use (yes/no) and type of diuretic (loop or thiazide).

Kidney Disease 40

Kidney Disease Diabetes Myocardial Infarction Heart Failure 40

Circulation

NOVEMBER 11, 2024

Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. vs 5.4%), and hospitalization for heart failure (RR 0.66; 95% CI [0.58, 0.76]; P < 0.00001; 3.2%

Myocardial Infarction 40

Myocardial Infarction Blood Pressure Heart Failure Kidney Disease 40

DAIC

SEPTEMBER 11, 2024

The study appears Sept. 11 in the Journal of the American College of Cardiology JACC.

Atrial Fibrillation 92

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 92

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81

European Journal of Heart Failure

JANUARY 20, 2025

The predictive ability of different risk scores developed and validated to predict the risk of mortality in patients with heart failure in the HELP-HF cohort is reported and compared based on their areas under the curve.

Heart Failure 40

Heart Failure Coronary Artery Disease Myocardial Infarction Kidney Disease 40

European Journal of Heart Failure

DECEMBER 12, 2023

Abstract Objectives This study aimed to assess the impact of anemia and iron deficiency (ID) on clinical outcome in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). Nevertheless, data concerning the impact of anemia and ID on clinical outcome in patients with CS are scarce.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes Catheterization Laboratory 40

Circulation

NOVEMBER 11, 2024

It is highly recommended to screen for liver fibrosis in patients with Type 2 diabetes mellitus (T2DM) and elevated liver enzymes using the fibrosis-4 (FIB-4) score.However, this recommendation does not extend to patients with chronic heart failure (CHF) who do not have T2DM. 1.45), cardiovascular mortality (HR: 1.80, 95% CI: 1.49-2.17),

Heart Failure 40

Heart Failure Diabetes Myocardial Infarction Kidney Disease 40

Journal of Cardiovascular Pharmacology

DECEMBER 11, 2024

To compare the efficacy of SGLT2 inhibitors among non-older and older patients we have searched PubMed, Cochrane Central, and Embase until February 2023 for randomized controlled trials (RCTs) investigating SGLT2 inhibitors in older (age 65 years) patients with diabetes mellitus, chronic kidney disease, and chronic heart failure.

Kidney Disease 40

Kidney Disease Heart Failure Myocardial Infarction Cardiovascular Disease 40

Dr. Smith's ECG Blog

APRIL 8, 2016

He also had a history of chronic kidney disease, stage III. Angio had shown some acute disease in the saphenous vein graft to the posterior descending artery off of the RCA. Literature on Hypokalemia as a risk for ventricular fibrillation in acute myocardial infarction. Most recent echo showed EF of 60%.

STEMI 52

STEMI Myocardial Infarction Cardiac Arrest Arrhythmia 52

DAIC

SEPTEMBER 11, 2024

The study appears Sept. 11 in the Journal of the American College of Cardiology JACC.

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 52

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Circulation: Cardiovascular Imaging

JANUARY 15, 2024

BACKGROUND:Advanced chronic kidney disease is associated with high cardiovascular risk, even after kidney transplant. METHODS:We retrospectively followed patients who underwent MPI before kidney transplant for the occurrence of MACE after transplant including myocardial infarction, stroke, heart failure, and cardiac death.

Transplant 40

Transplant Coronary Artery Disease Myocardial Infarction Kidney Disease 40

Journal of the American Heart Association

MARCH 21, 2025

Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and nonVeterans Affairs encounters.ResultsThe mean age was 70.6 were male, and 18.5%

Peripheral Arterial Disease 45

Peripheral Arterial Disease Outcomes Myocardial Infarction Kidney Disease 45

Open Heart

JULY 10, 2023

Higher-predicted risk, compared with lower-predicted risk, was associated with incident chronic kidney disease (cumulative incidence per 1000 persons at 10 years 245.2; years), heart failure (124.7; to 8.34; 4.27), myocardial infarction (69.6; to 5.22; 4.32), peripheral vascular disease (44.6;

Atrial Fibrillation 52

Atrial Fibrillation Myocardial Infarction Kidney Disease Innovation 52

Circulation

NOVEMBER 16, 2023

2.57]), chronic kidney disease (adjusted HR, 1.68 [95% CI, 1.36–2.09]), 2.15]), heart failure (adjusted HR, 1.51 [95% CI, 1.16–1.95]), 1.95]), myocardial infarction (adjusted HR, 1.41 [95% CI, 1.05–1.90]), Clinical factors associated with higher mortality included male sex (adjusted HR, 1.31 [95% CI, 1.08–1.58]),

Cholesterol 40

Cholesterol Myocardial Infarction Kidney Disease Heart Failure 40

Cardiometabolic Health Congress

DECEMBER 7, 2023

AF is associated with an increased risk of death as well as multiple adverse outcomes, including stroke, cognitive impairment or dementia, myocardial infarction, sudden cardiac death, heart failure (HF), chronic kidney disease (CKD), and peripheral artery disease (PAD).

Atrial Fibrillation 111

Atrial Fibrillation Risk Factors Ablation Strokes 111

Frontiers in Cardiovascular Medicine

NOVEMBER 21, 2024

The eGFR estimates were calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. CVD was defined as a self-reported physician's diagnosis of congestive heart failure, coronary heart disease, angina pectoris, myocardial infarction, or stroke. ml/min/1.73 m².

Cardiovascular Disease 52

Cardiovascular Disease Myocardial Infarction Kidney Disease Angina 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103

Dr. Smith's ECG Blog

FEBRUARY 26, 2025

It could also, given a different clinical context be compatible with a subacute myocardial infarction complicated by post infarct regional pericarditis. Most common cause) 2 ) Post infarct regional pericarditis. Due to the atypical and vague symptoms, the myocardial infarct was not initially diagnosed.

Chest Pain 89

Chest Pain Pericarditis Myocardial Infarction Dementia 89